09 Jul 2024 | 03:00 PM GMT

Do Accelerators Work to Nurture Innovation?

Participants:

Jochen Hurlebaus President & OwnerXO Life
Jochen Hurlebaus
President & OwnerXO Life
Sophie Park Managing DirectorBayer G4A
Sophie Park
Managing DirectorBayer G4A
Francesca Wuttke Founder & CEOnen Health
Francesca Wuttke
Founder & CEOnen Health
Aahuti Rai NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Aahuti Rai
NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Andrii Savytskyi Head of BD DeHealth
Andrii Savytskyi
Head of BD DeHealth
Arun Bhatia Commercial Strategy Lead - Digital HealthAstellas Pharma Rx+ Business Accelerator
Arun Bhatia
Commercial Strategy Lead - Digital HealthAstellas Pharma Rx+ Business Accelerator
Danielle Ralic CEOAncora.ai
Danielle Ralic
CEOAncora.ai
Danny Bosch Associate Director BD and CommercialImperial College Health Partners
Danny Bosch
Associate Director BD and CommercialImperial College Health Partners
Eric Thrailkill Executive Director, U.S. OperationsGlobal Health Connector
Eric Thrailkill
Executive Director, U.S. OperationsGlobal Health Connector
Gerrit Knippschild Co-FounderRegHub
Gerrit Knippschild
Co-FounderRegHub
Jacob Jesson AdvisorJesson Partners
Jacob Jesson
AdvisorJesson Partners
Jennifer Scanlon VP, Global Strategic PartnershipsNorthwell Health
Jennifer Scanlon
VP, Global Strategic PartnershipsNorthwell Health
Naomi Fried CEOPharmStars
Naomi Fried
CEOPharmStars
Taiba Quraishi Innovation AssociateAlexion Pharmaceuticals
Taiba Quraishi
Innovation AssociateAlexion Pharmaceuticals
Ursula Costa DirectorDayone
Ursula Costa
DirectorDayone
Weronika Michaluk MedTech Practice LeadHTD Health
Weronika Michaluk
MedTech Practice LeadHTD Health

About this Meeting

Accelerators play a crucial role in nurturing innovation in pharma by bringing together diverse and innovative stakeholders to create a collaborative ecosystem that fosters the exchange of ideas, expertise, and best practices most conducive to breakthrough discoveries and advancements.    

Accelerators are not a one-size-fits-all solution for disruptors in the digital health space.  The value of these programmes depends on factors such as mentorship quality, network relevance, and alignment with company growth needs. Furthermore, an accelerator’s success in this space relies on its ability to adapt to the ever-changing technology needs of pharma and its customers, staying ahead of emerging trends and technologies.   

Join this discussion to collectively determine how accelerators can be the best fit for innovation:   

  • What are the key benefits and potential drawbacks of participating in acceleration programmes for startups?   
  • What factors should startups consider to ensure that an acceleration programme aligns with their specific needs, goals, and values?   
  • What can pharma do to ensure that acceleration programmes benefit both entities equally? Where can pharma let accelerators bring the greatest value to digital health?  

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.